Skip to main content
Contact Us
Subscribe
E-Edition
69°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aytu Biopharma Inc
(NQ:
AYTU
)
1.640
-0.180 (-9.89%)
Streaming Delayed Price
Updated: 3:59 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aytu Biopharma Inc
< Previous
1
2
3
4
Next >
Aytu BioPharma Announces Launch of Public Offering
August 08, 2022
Via
ACCESSWIRE
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 26, 2022
Via
ACCESSWIRE
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 26, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
July 20, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
July 20, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of...
From
Aytu BioPharma, Inc.
Via
AccessWire
Exposures
Product Safety
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
June 29, 2022
ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
June 13, 2022
ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
May 16, 2022
Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
April 25, 2022
Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
April 19, 2022
ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S....
From
Aytu BioPharma, Inc.
Via
AccessWire
Exposures
Product Safety
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
March 23, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 22, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma to Participate in the 34th Annual Roth Conference
March 08, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
March 07, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 7, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
March 02, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
March 02, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the European...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
February 14, 2022
Quarterly Net Revenue Increased 53% Year-over-year to $23.1 Million PREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022 Initiation of Randomized,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioScience, Inc. (NASDAQ:AYTU) Investor Alert: Investigation over Possible Violations of Securities Laws
January 31, 2022
San Diego, CA -- (SBWIRE) -- 01/31/2022 -- An investigation was announced on behalf of investors of Aytu BioScience, Inc. (NASDAQ:AYTU) shares over potential securities laws violations by Aytu...
Via
SBWire
Aytu BioPharma Completes $15 Million Debt Refinancing
January 31, 2022
ENGLEWOOD, CO / ACCESSWIRE / January 31, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that it has...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
January 04, 2022
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
January 03, 2022
ENGLEWOOD, CO / ACCESSWIRE / January 3, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today...
From
Aytu BioPharma, Inc.
Via
AccessWire
Investigation Announced for Investors in NASDAQ:AYTU Shares of Possible Violations of Securities Laws by Aytu BioScience, Inc
December 14, 2021
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Aytu BioScience, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Via
SBWire
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
December 13, 2021
Pivotal clinical trial will begin in first half of 2022 ENGLEWOOD, CO / ACCESSWIRE / December 13, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
December 08, 2021
ENGLEWOOD, CO / ACCESSWIRE / December 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Aytu BioScience, Inc. (NASDAQ: AYTU) Shareholder Notice: Investigation over Potential Wrongdoing
November 30, 2021
San Diego, CA -- (SBWIRE) -- 11/30/2021 -- Certain directors of Aytu BioScience, Inc are under investigation on over potential breaches of fiduciary dutie.
Via
SBWire
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
November 23, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
November 17, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Aytu BioPharma Reports First Quarter 2022 Financial Results
November 15, 2021
Quarterly net revenue increased 62% to $21.9 million Ended quarter with approximately $40.6 million in cash, cash equivalents and restricted cash Fully integrated and expanding RxConnect patient...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Aytu BioPharma, Inc. (NASDAQ:AYTU) Investor Alert: Investigation over Possible Violations of Securities Laws
November 09, 2021
San Diego, CA -- (SBWIRE) -- 11/09/2021 -- An investigation was announced for investors of Aytu BioPharma, Inc. (NASDAQ:AYTU) shares over potential securities laws violations by Aytu BioPharma, Inc....
Via
SBWire
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
November 08, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.